Immunocore
28.50
-1.53 (-5.09%)
At close: Jan 14, 2025, 3:59 PM
27.00
-5.26%
After-hours Jan 14, 2025, 04:23 PM EST
undefined%
Bid 11.49
Market Cap 1.43B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.95
PE Ratio (ttm) -30
Forward PE n/a
Analyst Buy
Ask 36.61
Volume 301,729
Avg. Volume (20D) 269,993
Open 30.20
Previous Close 30.03
Day's Range 28.50 - 30.24
52-Week Range 27.69 - 76.98
Beta undefined

About IMCR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (N...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 497
Stock Exchange NASDAQ
Ticker Symbol IMCR

Analyst Forecast

According to 12 analyst ratings, the average rating for IMCR stock is "Buy." The 12-month stock price forecast is $66.5, which is an increase of 133.33% from the latest price.

Buy 58.33%
Hold 33.33%
Sell 8.33%
Stock Forecasts

Next Earnings Release

Immunocore is scheduled to release its earnings on Feb 26, 2025, before market opens.
Analysts project revenue of $83.72M, reflecting a 19.32% YoY growth and earnings per share of -0.4, making a 0.00% YoY.